Movement Alert｜CSPC PHARMA Rises 3.19% in Regular Trading, Monkeypox mRNA Vaccine Receives FDA Clinical Trial Approval

Market Focus08-11 11:39

On August 11, CSPC PHARMA rose 3.19% in regular trading, reaching HKD 8.895 per share, with turnover of HKD 302 million.

On the news front, the company announced on August 10 that its monkeypox mRNA vaccine SYS 6037, co-developed with the Chinese Academy of Sciences Institute of Microbiology, has received FDA approval to conduct clinical trials in the United States. SYS 6037 is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, expected to become a competitive product that further enriches the company's mRNA vaccine pipeline.

The gain also extends a rally from the prior session, when the stock advanced 4.43% on deepening AstraZeneca cooperation. On August 5, CSPC received a USD 10 million milestone payment under the strategic R&D collaboration agreement and signed a joint venture contract to build a next-generation biologics production base in Shijiazhuang, with CSPC holding 51% and AstraZeneca 49%. Additionally, the company's interim profit is expected to surge 131.4%-141.3% year-over-year to RMB 5.9-6.2 billion, driven by authorization fee income from the AstraZeneca deal and approximately 10% growth in drug product sales.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115899428?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 11:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115899428","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CSPC PHARMA Rises 3.19% in Regular Trading, Monkeypox mRNA Vaccine Receives FDA Clinical Trial Approval","media":"Market Focus","content":"<p><p>On August 11, CSPC PHARMA rose 3.19% in regular trading, reaching HKD 8.895 per share, with turnover of HKD 302 million.</p><p>On the news front, the company announced on August 10 that its monkeypox mRNA vaccine SYS 6037, co-developed with the Chinese Academy of Sciences Institute of Microbiology, has received FDA approval to conduct clinical trials in the United States. SYS 6037 is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, expected to become a competitive product that further enriches the company's mRNA vaccine pipeline.</p><p>The gain also extends a rally from the prior session, when the stock advanced 4.43% on deepening AstraZeneca cooperation. On August 5, CSPC received a USD 10 million milestone payment under the strategic R&D collaboration agreement and signed a joint venture contract to build a next-generation biologics production base in Shijiazhuang, with CSPC holding 51% and AstraZeneca 49%. Additionally, the company's interim profit is expected to surge 131.4%-141.3% year-over-year to RMB 5.9-6.2 billion, driven by authorization fee income from the AstraZeneca deal and approximately 10% growth in drug product sales.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC PHARMA Rises 3.19% in Regular Trading, Monkeypox mRNA Vaccine Receives FDA Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC PHARMA Rises 3.19% in Regular Trading, Monkeypox mRNA Vaccine Receives FDA Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 11:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 11, CSPC PHARMA rose 3.19% in regular trading, reaching HKD 8.895 per share, with turnover of HKD 302 million.</p><p>On the news front, the company announced on August 10 that its monkeypox mRNA vaccine SYS 6037, co-developed with the Chinese Academy of Sciences Institute of Microbiology, has received FDA approval to conduct clinical trials in the United States. SYS 6037 is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, expected to become a competitive product that further enriches the company's mRNA vaccine pipeline.</p><p>The gain also extends a rally from the prior session, when the stock advanced 4.43% on deepening AstraZeneca cooperation. On August 5, CSPC received a USD 10 million milestone payment under the strategic R&D collaboration agreement and signed a joint venture contract to build a next-generation biologics production base in Shijiazhuang, with CSPC holding 51% and AstraZeneca 49%. Additionally, the company's interim profit is expected to surge 131.4%-141.3% year-over-year to RMB 5.9-6.2 billion, driven by authorization fee income from the AstraZeneca deal and approximately 10% growth in drug product sales.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1115899428","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115899428","pubTimestamp":1786419568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 11, CSPC PHARMA rose 3.19% in regular trading, reaching HKD 8.895 per share, with turnover of HKD 302 million.On the news front, the company announced on August 10 that its monkeypox mRNA...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势预警|石药集团常规交易涨3.19%，猴痘mRNA疫苗获FDA临床试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On August 11, CSPC PHARMA rose 3.19% in regular trading, reaching HKD 8.895 per share, with turnover of HKD 302 million.On the news front, the company announced on August 10 that its monkeypox mRNA vaccine SYS 6037, co-developed with the Chinese Academy of Sciences Institute of Microbiology, has received FDA approval to conduct clinical trials in the United States. SYS 6037 is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, expected to become a competitive product that further enriches the company's mRNA vaccine pipeline.The gain also extends a rally from the prior session, when the stock advanced 4.43% on deepening AstraZeneca cooperation. On August 5, CSPC received a USD 10 million milestone payment under the strategic R&D collaboration agreement and signed a joint venture contract to build a next-generation biologics production base in Shijiazhuang, with CSPC holding 51% and AstraZeneca 49%. Additionally, the company's interim profit is expected to surge 131.4%-141.3% year-over-year to RMB 5.9-6.2 billion, driven by authorization fee income from the AstraZeneca deal and approximately 10% growth in drug product sales.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115899428","isCrawlerRequest":true}